FHL-1 is not involved in pressure overload-induced maladaptive right ventricular remodeling and dysfunction

Basic Res Cardiol. 2020 Jan 24;115(2):17. doi: 10.1007/s00395-019-0767-5.

Abstract

Aims: The cytoskeletal signaling protein four and-a-half LIM domains 1 (FHL-1) has recently been identified as a novel key player in pulmonary hypertension as well as in left heart diseases. In this regard, FHL-1 has been implicated in dysregulated hypertrophic signaling in pulmonary arterial smooth muscle cells leading to pulmonary hypertension. In mice, FHL-1-deficiency (FHL-1-/-) led to an attenuated hypertrophic signaling associated with a blunted hypertrophic response of the pressure-overloaded left ventricle (LV). However, the role of FHL-1 in right heart hypertrophy has not yet been addressed.

Methods and results: We investigated FHL-1 expression in C57Bl/6 mice subjected to chronic biomechanical stress and found it to be enhanced in the right ventricle (RV). Next, we subjected FHL-1-/- and corresponding wild-type mice to pressure overload of the RV by pulmonary arterial banding for various time points. However, in contrast to the previously published study in LV-pressure overload, which was confirmed here, RV hypertrophy and hypertrophic signaling was not diminished in FHL-1-/- mice. In detail, right ventricular pressure overload led to hypertrophy, dilatation and fibrosis of the RV from both FHL-1-/- and wild-type mice. RV remodeling was associated with impaired RV function as evidenced by reduced tricuspid annular plane systolic excursion. Additionally, PAB induced upregulation of natriuretic peptides and slight downregulation of phospholamban and ryanodine receptor 2 in the RV. However, there was no difference between genotypes in the degree of expression change.

Conclusion: FHL-1 pathway is not involved in the control of adverse remodeling in the pressure overloaded RV.

Keywords: Cytoskeletal proteins; Four and-a-half LIM domain 1 protein; Pressure overload; Pulmonary arterial banding; Right ventricular hypertrophy.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Calcium-Binding Proteins / metabolism
  • Disease Models, Animal
  • Fibrosis
  • Heart Ventricles / metabolism*
  • Heart Ventricles / pathology
  • Heart Ventricles / physiopathology
  • Hypertrophy, Right Ventricular / genetics
  • Hypertrophy, Right Ventricular / metabolism*
  • Hypertrophy, Right Ventricular / pathology
  • Hypertrophy, Right Ventricular / physiopathology
  • Intracellular Signaling Peptides and Proteins / deficiency
  • Intracellular Signaling Peptides and Proteins / genetics
  • Intracellular Signaling Peptides and Proteins / metabolism*
  • LIM Domain Proteins / deficiency
  • LIM Domain Proteins / genetics
  • LIM Domain Proteins / metabolism*
  • Male
  • Mice, Inbred C57BL
  • Mice, Knockout
  • Muscle Proteins / deficiency
  • Muscle Proteins / genetics
  • Muscle Proteins / metabolism*
  • Natriuretic Peptides / metabolism
  • Ryanodine Receptor Calcium Release Channel / metabolism
  • Signal Transduction
  • Ventricular Dysfunction, Right / genetics
  • Ventricular Dysfunction, Right / metabolism*
  • Ventricular Dysfunction, Right / pathology
  • Ventricular Dysfunction, Right / physiopathology
  • Ventricular Function, Right*
  • Ventricular Remodeling*

Substances

  • Calcium-Binding Proteins
  • Fhl1 protein, mouse
  • Intracellular Signaling Peptides and Proteins
  • LIM Domain Proteins
  • Muscle Proteins
  • Natriuretic Peptides
  • Ryanodine Receptor Calcium Release Channel
  • phospholamban
  • ryanodine receptor 2. mouse